PharmaNutra SpAMIL:PHN -1.91%85 EBITDA Margin % is 19.03% as of Mar. 2026, which is 29% below its 10-year median of 26.80. GuruFocus rates MIL:PHN with a GF Score™ of 85/100 and a GF Value™ of €71.38 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, PharmaNutra SpA ranks better than 79.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PharmaNutra SpA's EBITDA for the
three
months ended in Mar. 2026 was €6.3 Mil. PharmaNutra SpA's Revenue for the
three
months ended in Mar. 2026 was €33.3 Mil. Therefore, PharmaNutra SpA's EBITDA margin for the quarter that ended in Mar. 2026 was 19.03%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PharmaNutra SpA EBITDA Margin % Related Terms
PharmaNutra SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (MIL:PHN) has a EBITDA Margin % of 19.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaNutra SpA and its competitors. This is 29% below median its historical median of 26.80. Over the past decade, PharmaNutra SpA's EBITDA Margin % has ranged from 21.71 to 29.53. According to the industry distribution chart, PharmaNutra SpA ranks #199 out of 955 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is PharmaNutra SpA's EBITDA Margin % too high?
PharmaNutra SpA's current EBITDA Margin % of 19.03% is 29% below median its 10-year median of 26.80. Over the past 10 years, this metric has ranged from a low of 21.71 to a high of 29.53. The Drug Manufacturers industry median EBITDA Margin % is 12.39. PharmaNutra SpA's value of 19.03% is 53.6% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #199 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #199 out of 955 companies for EBITDA Margin %. This places PharmaNutra SpA in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. PharmaNutra SpA's value of 19.03% is 53.6% above this benchmark. Historically, PharmaNutra SpA's own EBITDA Margin % has ranged from 21.71 to 29.53 over the past decade. While the company's 10-year median is 26.80 vs. the industry median of 12.39, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current EBITDA Margin % of 19.03% is 53.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current EBITDA Margin % is 19.03%, which is 29% below median its own 10-year median of 26.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €71.38, compared to a current price of €87.20 — trading 22.2% above its estimated fair value. The current EBITDA Margin % is 19.03%, which is 29% below median its 10-year median of 26.80 and 53.6% above the Drug Manufacturers industry median of 12.39. PharmaNutra SpA's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current EBITDA Margin % is 19.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €87.20 is trading 22.2% above its estimated GF Value™ of €71.38.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
EBITDA Margin %: 19.03% (29% below median its 10-year median of 26.80)
GF Value™: €71.38 vs. price of €87.20 (22.2% above fair value)
Industry Position: 53.6% above the Drug Manufacturers median (#199 of 955)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
85GF Score
Get the complete analysis for MIL:PHN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
